following a full submission
naloxegol (Moventig®) is accepted for use within NHS Scotland.
Indication under review: the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).
Naloxegol compared to placebo significantly improved the response rate in patients with opioid-induced constipation including patients who had previously had an inadequate response to at least four days of treatment with at least one class of laxative.
|Drug Name:||naloxegol (Moventig)|
|SMC Drug ID:||1106/15|
|Manufacturer:||AstraZeneca UK Ltd|
|Indication:||the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).|
|Sub Category:||1.6 Laxatives|
|Submission Type:||Full submission|
|Date Advice Published:||7 December 2015|